Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure

Takaaki Furihata, Shintaro Kinugawa, Arata Fukushima, Shingo Takada, Tsuneaki Homma, Yoshihiro Masaki, Takahiro Abe, Takashi Yokota, Koji Oba, Koichi Okita, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background It has been reported that skeletal muscle mass and strength are decreased in patients with heart failure (HF), and HF is associated with both reduced exercise capacity and adverse clinical outcomes. Myostatin has been known as a negative regulator of muscle growth, follistatin as the myostatin antagonist, maintaining tissue homeostasis. We thus determined serum myostatin levels in HF patients and whether they are associated with skeletal muscle wasting. Methods and results Forty one consecutive HF patients (58 ± 15 years old, New York Heart Association class I–III) and 30 age-matched healthy subjects as controls (53 ± 8 years old) were studied. Serum myostatin levels were significantly lower in HF patients than controls (18.7 ± 7.4 vs. 23.6 ± 5.2 ng/mL, P < 0.001). Circumference of the thickest part of the right thigh was significantly small (468 ± 72 vs. 559 ± 37 mm, P = 0.001) and lower extremity muscular strength was lower in patients with HF (129 ± 55 vs. 219 ± 52 N × m, P < 0.001). Fourteen HF patients (34%) had muscle wasting. By univariate analysis, higher age, higher serum follistatin, and lower serum myostatin were significantly associated with the presence of muscle wasting. By multivariate analysis, serum myostatin levels were independently associated with muscle wasting (OR = 0.77, 95% CI [0.58, 0.93], P = 0.02). Conclusion Serum myostatin levels were significantly decreased in HF patients and associated with lower extremity muscle wasting, suggesting that myostatin may be an important factor for maintaining skeletal muscle mass and strength in HF.

Original languageEnglish
Pages (from-to)483-487
Number of pages5
JournalInternational Journal of Cardiology
Volume220
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Myostatin
Skeletal Muscle
Heart Failure
Serum
Muscles
Follistatin
Muscle Strength
Lower Extremity
Thigh
Healthy Volunteers
Homeostasis
Multivariate Analysis
Exercise

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. / Furihata, Takaaki; Kinugawa, Shintaro; Fukushima, Arata; Takada, Shingo; Homma, Tsuneaki; Masaki, Yoshihiro; Abe, Takahiro; Yokota, Takashi; Oba, Koji; Okita, Koichi; Tsutsui, Hiroyuki.

In: International Journal of Cardiology, Vol. 220, 01.10.2016, p. 483-487.

Research output: Contribution to journalArticle

Furihata, T, Kinugawa, S, Fukushima, A, Takada, S, Homma, T, Masaki, Y, Abe, T, Yokota, T, Oba, K, Okita, K & Tsutsui, H 2016, 'Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure', International Journal of Cardiology, vol. 220, pp. 483-487. https://doi.org/10.1016/j.ijcard.2016.06.231
Furihata, Takaaki ; Kinugawa, Shintaro ; Fukushima, Arata ; Takada, Shingo ; Homma, Tsuneaki ; Masaki, Yoshihiro ; Abe, Takahiro ; Yokota, Takashi ; Oba, Koji ; Okita, Koichi ; Tsutsui, Hiroyuki. / Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. In: International Journal of Cardiology. 2016 ; Vol. 220. pp. 483-487.
@article{334842bc745240d88aeb03f7bf923891,
title = "Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure",
abstract = "Background It has been reported that skeletal muscle mass and strength are decreased in patients with heart failure (HF), and HF is associated with both reduced exercise capacity and adverse clinical outcomes. Myostatin has been known as a negative regulator of muscle growth, follistatin as the myostatin antagonist, maintaining tissue homeostasis. We thus determined serum myostatin levels in HF patients and whether they are associated with skeletal muscle wasting. Methods and results Forty one consecutive HF patients (58 ± 15 years old, New York Heart Association class I–III) and 30 age-matched healthy subjects as controls (53 ± 8 years old) were studied. Serum myostatin levels were significantly lower in HF patients than controls (18.7 ± 7.4 vs. 23.6 ± 5.2 ng/mL, P < 0.001). Circumference of the thickest part of the right thigh was significantly small (468 ± 72 vs. 559 ± 37 mm, P = 0.001) and lower extremity muscular strength was lower in patients with HF (129 ± 55 vs. 219 ± 52 N × m, P < 0.001). Fourteen HF patients (34{\%}) had muscle wasting. By univariate analysis, higher age, higher serum follistatin, and lower serum myostatin were significantly associated with the presence of muscle wasting. By multivariate analysis, serum myostatin levels were independently associated with muscle wasting (OR = 0.77, 95{\%} CI [0.58, 0.93], P = 0.02). Conclusion Serum myostatin levels were significantly decreased in HF patients and associated with lower extremity muscle wasting, suggesting that myostatin may be an important factor for maintaining skeletal muscle mass and strength in HF.",
author = "Takaaki Furihata and Shintaro Kinugawa and Arata Fukushima and Shingo Takada and Tsuneaki Homma and Yoshihiro Masaki and Takahiro Abe and Takashi Yokota and Koji Oba and Koichi Okita and Hiroyuki Tsutsui",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ijcard.2016.06.231",
language = "English",
volume = "220",
pages = "483--487",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure

AU - Furihata, Takaaki

AU - Kinugawa, Shintaro

AU - Fukushima, Arata

AU - Takada, Shingo

AU - Homma, Tsuneaki

AU - Masaki, Yoshihiro

AU - Abe, Takahiro

AU - Yokota, Takashi

AU - Oba, Koji

AU - Okita, Koichi

AU - Tsutsui, Hiroyuki

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background It has been reported that skeletal muscle mass and strength are decreased in patients with heart failure (HF), and HF is associated with both reduced exercise capacity and adverse clinical outcomes. Myostatin has been known as a negative regulator of muscle growth, follistatin as the myostatin antagonist, maintaining tissue homeostasis. We thus determined serum myostatin levels in HF patients and whether they are associated with skeletal muscle wasting. Methods and results Forty one consecutive HF patients (58 ± 15 years old, New York Heart Association class I–III) and 30 age-matched healthy subjects as controls (53 ± 8 years old) were studied. Serum myostatin levels were significantly lower in HF patients than controls (18.7 ± 7.4 vs. 23.6 ± 5.2 ng/mL, P < 0.001). Circumference of the thickest part of the right thigh was significantly small (468 ± 72 vs. 559 ± 37 mm, P = 0.001) and lower extremity muscular strength was lower in patients with HF (129 ± 55 vs. 219 ± 52 N × m, P < 0.001). Fourteen HF patients (34%) had muscle wasting. By univariate analysis, higher age, higher serum follistatin, and lower serum myostatin were significantly associated with the presence of muscle wasting. By multivariate analysis, serum myostatin levels were independently associated with muscle wasting (OR = 0.77, 95% CI [0.58, 0.93], P = 0.02). Conclusion Serum myostatin levels were significantly decreased in HF patients and associated with lower extremity muscle wasting, suggesting that myostatin may be an important factor for maintaining skeletal muscle mass and strength in HF.

AB - Background It has been reported that skeletal muscle mass and strength are decreased in patients with heart failure (HF), and HF is associated with both reduced exercise capacity and adverse clinical outcomes. Myostatin has been known as a negative regulator of muscle growth, follistatin as the myostatin antagonist, maintaining tissue homeostasis. We thus determined serum myostatin levels in HF patients and whether they are associated with skeletal muscle wasting. Methods and results Forty one consecutive HF patients (58 ± 15 years old, New York Heart Association class I–III) and 30 age-matched healthy subjects as controls (53 ± 8 years old) were studied. Serum myostatin levels were significantly lower in HF patients than controls (18.7 ± 7.4 vs. 23.6 ± 5.2 ng/mL, P < 0.001). Circumference of the thickest part of the right thigh was significantly small (468 ± 72 vs. 559 ± 37 mm, P = 0.001) and lower extremity muscular strength was lower in patients with HF (129 ± 55 vs. 219 ± 52 N × m, P < 0.001). Fourteen HF patients (34%) had muscle wasting. By univariate analysis, higher age, higher serum follistatin, and lower serum myostatin were significantly associated with the presence of muscle wasting. By multivariate analysis, serum myostatin levels were independently associated with muscle wasting (OR = 0.77, 95% CI [0.58, 0.93], P = 0.02). Conclusion Serum myostatin levels were significantly decreased in HF patients and associated with lower extremity muscle wasting, suggesting that myostatin may be an important factor for maintaining skeletal muscle mass and strength in HF.

UR - http://www.scopus.com/inward/record.url?scp=84978153438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978153438&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.06.231

DO - 10.1016/j.ijcard.2016.06.231

M3 - Article

VL - 220

SP - 483

EP - 487

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -